New drug duo aims to Re-Sensitize tough lung cancers to treatment
NCT ID NCT05467748
Summary
This study is testing whether adding a new oral drug called tulmimetostat to an existing immunotherapy (pembrolizumab) can help control advanced non-small cell lung cancer. It is for patients whose cancer has continued to grow despite previous treatments that included immunotherapy. The main goals are to see if the combination is safe and if it can shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Michael E. DeBakey VA Medical Center, Houston, TX
RECRUITINGHouston, Texas, 77030-4211, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
VA Ann Arbor Healthcare System, Ann Arbor, MI
RECRUITINGAnn Arbor, Michigan, 48105-2303, United States
Contact Email: •••••@•••••
-
VA Long Beach Healthcare System, Long Beach, CA
NOT_YET_RECRUITINGLong Beach, California, 90822, United States
Contact Email: •••••@•••••
-
VA Northern California Health Care System, Mather, CA
NOT_YET_RECRUITINGSacramento, California, 95655-4200, United States
Contact Email: •••••@•••••
-
VA San Diego Healthcare System, San Diego, CA
RECRUITINGSan Diego, California, 92161-0002, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.